Skip to Content

KemPharm Inc KMPH Stock Quote

| Rating as of

Morningstar‘s Stock Analysis KMPH

Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Key Statistics KMPH

Company Profile KMPH

Business Description

KemPharm Inc is a clinical-stage specialty pharmaceutical company engaged in the discovery and development of treatments for the central nervous system, CNS, and rare disease indications. The company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. Its LAT platform technology discovers and develops prodrugs that improve one or more of the attributes of approved drugs, such as susceptibility to abuse, bioavailability, and safety. KemPharm's two lead product candidates are KP415, and KP484, which are both based on a prodrug of d-methylphenidate, or d-MPH; KP879, is also based on a prodrug of d-MPH.

1180 Celebration Boulevard, Suite 103
Celebration, FL, 34747
T +1 321 939-3416
Industry Biotechnology
Most Recent Earnings Jun 30, 2022
Fiscal Year End Dec 31, 2022
Employees 24